RNS Number : 8211W
Fusion Antibodies PLC
18 July 2024

REACH - Non-regulatory announcement*

18 July 2024

Fusion Antibodies plc
("Fusion"or the **"Company")**

Launch of New Interactive Investor Hub

Enablingproactive communication and enquiry support to shareholders

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announcesthe launch of its new interactive investor hub which is accessible from the Company's website.

For both existing and prospective shareholders, the new interactive investor hub brings all of the Company's existing content into a single integrated platform, and will enable investors and stakeholders to be better informed and engaged, including but not limited to, the Company's:

Regulatory announcements
Reports
Presentations
Educational material
Interviews
Corporate research

The new investor hub also offers an interactive online experience, enabling the Company's stakeholders to comment on and ask the Fusion team questions via a dedicated portal which the Company will monitor and through which it will provide appropriate responses in a timely manner.

To sign up to the new interactive investor hub, stakeholders are encouraged to:

1. Visitinvestorhub.fusionantibodies.com
2. Follow the prompts to sign up for an investor hub account
3. Complete your account profile

The information disclosed pursuant to Rule 26 of the AIM Rules for Companies will continue to be available at the Company's website:www.fusionantibodies.com.

Adrian Kinkaid, CEO of Fusion Antibodies plc, commented:*"Engaging with our shareholders has always been fundamental at Fusion. The launch of our new interactive investor hub marks an exciting step forward, providing a dynamic platform for current and potential investors to connect with us as well as to gain a comprehensive understanding of our mission, our technology and our business.*

"The new interactive investor hub will act as a rich resource, offering video content, detailed information, and insights into our ongoing activities and future strategies. We encourage our stakeholders to explore the new investor hub and share their thoughts as we aim to enhance and refine our communication channels."

Enquiries:

Fusion Antibodies plc www.fusionantibodies.com

Adrian Kinkaid, Chief Executive Officer — Via Walbrook PR
Stephen Smyth, Chief Financial Officer

Allenby Capital Limited — Tel: +44 (0) 20 3328 5656
James Reeve/Vivek Bhardwaj (Corporate Finance)
Tony Quirke/Joscelin Pinnington (Sales and Corporate Broking)

Shard Capital Partners LLP
Damon Heath (Joint Broker) — Tel: +44 (0) 207 186 9952

Walbrook PR — Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com
Anna Dunphy — Mob: +44 (0)7876 741 001

About Fusion Antibodies plc

Fusion is a Belfast based contract research organisation ("CRO") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx ^{TM} platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.

The Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.

Fusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.

***About Reach announcements**

This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services.

For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAEDLFFZDLXBBF